Context Therapeutics Inc. Common Stock (CNTX)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 15
- Market Cap
- $56M
About Context Therapeutics Inc. Common Stock
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
SentiSense also tracks daily options readings for Context Therapeutics Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Context Therapeutics Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.